Drug Trial Radar · NCT07427628
A Proof-of-concept Trial to EvaluAte the efficaCy and Safety Of Cell Therapy TRX103 in Patients With Active, Non-infectious Uveitis
Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
18
Planned (sponsor's estimate)
Start
Mar 18, 2026
Primary completion
Dec 2028
Study completion Dec 2028
Sponsor
- Lead sponsor
- Quan Dong NguyenAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Feb 23, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this Phase 1, first in uveitis open-label study is to assess the safety and tolerability of TRX-103 in patients with non infectious uveitis (NIU). It is anticipated that up to 18 Subjects will be enrolled during a 18-24 month enrollment period. TRX-103 will be infused one time.
Conditions
- Non Infectious Uveitis
Interventions
TRX103Biological
TRX103 infusion via peripheral line
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment emergent Adverse events and Serious Adverse events at week 52Time frame: Up to a year
- Incidence of infections, either bacterial, fungal or viral at week 52Time frame: Upto 1 year
- Negative Replication Competent Lentivirus (RCL) at approximately 3-months, 6-months, and 12-months.Time frame: At 3-month, 6-month, and 1-year.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Byers Eye Institute
Palo Alto, California · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.